ESC 2021: Late-breaking Science Video Collection
Published: 02 September 2021
-
Views:
6256
-
Likes:
7
-
Views:
6256
-
Likes:
7
-
Up Next -
10m 53sPart 3 | Session 11 RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
-
20m 32s
-
25m 18sPart 1 | Session 1 View from the Thoraxcenter – What's Hot at ESC 2021 Nicolas M Van Mieghem, Joost Daemen
-
36m 1sPart 1 | Session 2 View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up Joost Daemen, Nicolas M Van Mieghem
-
19m 47sPart 2 | Session 1 ESC 2021 Discussion: The EMPEROR-Preserved Trial Harriette Van Spall, Stefan Anker
-
15m 2sPart 2 | Session 2 ESC 2021 Discussion: The FIGARO-DKD Trial Bertram Pitt, Harriette Van Spall
-
20m 8sPart 2 | Session 3 ESC 2021 Discussion: The EMPEROR-Pooled Study Milton Packer, Harriette Van Spall
-
6m 33sPart 3 | Session 1 ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI George D Dangas
-
4m 39sPart 3 | Session 2 SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI Adrian P Banning
-
8m 40sPart 3 | Session 3 TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI Davide Cao
-
5m 21sPart 3 | Session 4 The LAAOS III Study: Surgical AFIB Ablation Evaluation Richard Whitlock
-
9mPart 3 | Session 5 TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type George D Dangas
-
5m 43sPart 3 | Session 6 STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS Hirotoshi Watanabe
-
5m 41sPart 3 | Session 7 SPLENDOR: Metabolic Surgery and Risk of MACE in NASH Ali Aminian
-
5m 11sPart 3 | Session 8 RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients Harald Thune Jorstad
-
6m 9sPart 3 | Session 9 VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes Cecilia Low Wang
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
In the latest episode View from the Thoraxcenter, Professor Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their concise analysis of the hot line and late-breaking trials that will be presented at ESC Congress 2021.
What presentations should we look at for this weekend? Get your update on the importance of trials such as GUIDE-HF, MASTER DAPT, TOMAHAWK and many more delivered by our world-class experts, Professor Van Mieghem and Dr Joost Daemen.
Part 2
Late-breaker Discussion Series
Host, Dr Harriette Van Spall interviews the late-breaker and hot line presenters of ESC Congress 2021.
Part 3
Expert Interviews
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
Part 4
Masterclass with Dr Harriette Van Spall & Dr Birgit Vogel
In the ESC Congress 2021 episode of the Masterclass video series, host, Dr Harriette Van Spall (McMaster University, CA) meets with Dr Birgit Vogel (Icahn School of Medicine at Mount Sinai, US), one of the commissioners and first author of the "The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030" report.